Evidence map›Paper›PMID 40506734›Full record

ArticleMolecular medicine (Cambridge, Mass.)2025

Cytokine production of mononuclear leukocytes in response to respiratory syncytial virus is increased in COPD but suppressed in non-COPD tobacco smokers.

Sarah D Yanik, Kaschin Jamal Jameel, Simon Rohde, Paul Bürger, Eike Bülthoff, Thomas Grunwald, Juliane Kronsbein, Andrea Koch, Michael R Edwards, Matthias Tenbusch and 1 more

Abstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Exploring CCND1 as a Key Target ofCurrent issues in molecular biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sarah D YanikMedical Clinic III for Pneumology, Allergology, Sleep- and Respiratory Medicine, Bergmannsheil University Hospital, Ruhr-University Bochum, Bürkle-de-la-Camp-Platz 1, Bochum, 44789, Germany.
Kaschin Jamal JameelMedical Clinic III for Pneumology, Allergology, Sleep- and Respiratory Medicine, Bergmannsheil University Hospital, Ruhr-University Bochum, Bürkle-de-la-Camp-Platz 1, Bochum, 44789, Germany.
Simon RohdeMedical Clinic III for Pneumology, Allergology, Sleep- and Respiratory Medicine, Bergmannsheil University Hospital, Ruhr-University Bochum, Bürkle-de-la-Camp-Platz 1, Bochum, 44789, Germany.
Paul BürgerMedical Clinic III for Pneumology, Allergology, Sleep- and Respiratory Medicine, Bergmannsheil University Hospital, Ruhr-University Bochum, Bürkle-de-la-Camp-Platz 1, Bochum, 44789, Germany.
Eike BülthoffMedical Clinic III for Pneumology, Allergology, Sleep- and Respiratory Medicine, Bergmannsheil University Hospital, Ruhr-University Bochum, Bürkle-de-la-Camp-Platz 1, Bochum, 44789, Germany.
Thomas GrunwaldFraunhofer Institute for Cell Therapy and Immunology, Perlickstr. 1, Leipzig, 04103, Germany.
Juliane KronsbeinMedical Clinic III for Pneumology, Allergology, Sleep- and Respiratory Medicine, Bergmannsheil University Hospital, Ruhr-University Bochum, Bürkle-de-la-Camp-Platz 1, Bochum, 44789, Germany.
Andrea KochJohannes Kepler Universität (JKU) und Kepler Universitätsklinikum (KUK) Linz; MC III, Innere Medizin 4, Pneumologie. Krankenhausstr. 9, Linz, 4020, Austria.
Michael R EdwardsNational Heart and Lung Institute, Imperial College, London, UK.
Matthias TenbuschInstitute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich- Alexander-Universität (FAU) Erlangen-Nürnberg, Schlossgarten 4, Erlangen, 91054, Germany.
Jürgen KnoblochMedical Clinic III for Pneumology, Allergology, Sleep- and Respiratory Medicine, Bergmannsheil University Hospital, Ruhr-University Bochum, Bürkle-de-la-Camp-Platz 1, Bochum, 44789, Germany. juergen.knobloch@bergmannsheil.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRespiratory syncytial virus (RSV) induces exacerbations of chronic obstructive pulmonary disease (COPD) that are critical for disease progression and burden. COPD subjects have an increased susceptibility to viral respiratory infections. We aimed to identify underlying systemic immune pathologies that could be used as drug targets to reduce exacerbations.

methodsPeripheral blood mononuclear cells were isolated from 16 healthy never smokers, 17 current smokers without airflow limitation, and 17 COPD subjects. The cells were cultured and infected with RSV for 24 h or seven days. IFNα, T-cell- and inflammatory cytokines, the expression of interferon-stimulating genes (ISGs), and virus load in supernatants were measured by ELISA or real-time PCR, respectively. Data were compared between the three patient groups.

resultsRSV induced CCL2, CCL5, IFNα, IFNγ, IL1-β, IL-6, IL-8, and TNFα but not IL-4, IL-5, IL-17, GM-CSF, and TGFβ. CCL2 was unchanged between the groups. All other cytokines were either increased or produced for a longer period of time in COPD but were reduced or not produced at all in smokers. Virus copy numbers were increased in COPD but reduced in smokers. RSV induced MxA, OAS, and Viperin expression with differences between the groups.

conclusionCirculating immune cells in COPD might cause cytokine overproduction in response to RSV after recruitment to the site of infection and might contribute to the increase in inflammation in exacerbations. This might be explained by differences in RSV replication efficacy and ISG expression. We provide first indication for ISGs and circulating cells as drug targets to reduce or prevent exacerbations.

Indexed as

CytokinesLeukocytes, MononuclearPulmonary Disease, Chronic ObstructiveRespiratory Syncytial VirusesRespiratory Syncytial Virus InfectionsSmokingAgedFemaleHumansMaleMiddle AgedSmokersViral LoadCytokinesCirculating immune cellsCOPDCytokine overproductionExacerbationRSV

Identifiers

PMID40506734
PMCPMC12160369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.